Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Europe. The aim of this study is investigate the potential of a supplementary insulin therapy regimen (SIT) as intensification for insufficiently controlled patients with type 2 diabetes in a normal diabetes care setting.
Interventions
DRUGinsulin aspart
Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
DRUGinsulin detemir
Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes * OAD monotherapy * OAD combination therapy * Therapy with OAD and basal insulin * Conventional insulin therapy with premixed insulin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c (glycosylated haemoglobin) | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose (FBG) | — |
| 2-hours postprandial blood glucose | — |
| Hypoglycemia | — |
| Weight development | — |
| Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs) | — |
Countries
Germany
Outcome results
None listed